Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Advanced Cholangiocarcinoma with FGFR Alterations
NCT02150967Phase 2Terminated
- Sponsor
- QED Therapeutics
- Start
- Jul 2014
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of infigratinib in cholangiocarcinoma (CCA), sponsored by QED Therapeutics. Started Jul 2014; status: terminated.
02
Drugs
infigratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02150967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02150967.